Erratum: Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in cremophor® EL (Clinical Drug Investigation DOI 10.1007/s40261-012-0029-x));Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor® EL

Clinical Drug Investigation

Volumn 33, Issue 1, 2013, Pages 25-34

  Ehinger, Karl Henrik Johannes ^a,b   Hansson, Magnus Joakim ^a,b   Sjövall, Fredrik ^a,b   Elmér, Eskil ^a,b  

^a NeuroVive Pharmaceutical AB (Publ)   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOMULSION; CREMOPHOR; CYCLOSPORIN A; HYDROCORTISONE; LIPID EMULSION; PROMETHAZINE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BREAST DISEASE; BURNING SENSATION; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEART DISEASE; HOT FLUSH; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT SAFETY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN DISEASE; VASCULAR DISEASE;

EID: 84873051665     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0050-0     Document Type: Erratum

References (60)

1. Giorgio V, Soriano ME, Basso E, et al. Cyclophilin D in mitochondrial pathophysiology. Biochim Biophys Acta. 2010;1797(6-7):1113-8.
2. Griveas I, Visvardis G, Papadopoulou D, et al. Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome. Artif Organs. 2010;34(3):234-7.
3. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008;26(5):438-47.
4. Fritsche L, Dragun D, Neumayer HH, et al. Impact of cyclosporine on the development of immunosuppressive therapy. Transpl Proc. 2004;36(2 Suppl):130S-4S.
5. Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46(2):129-37.
6. Hijnen DJ, ten Berge O, Timmer-de Mik L, et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 2007;21(1):85-9.
7. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-84.
8. Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transpl. 2010;16(1 Suppl):S18-27.
9. Norenberg MD, Rao KV. The mitochondrial permeability transition in neurologic disease. Neurochem Int. 2007;50(7-8):983-97.
10. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359(5):473-81.
11. Scheff SW, Sullivan PG. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J Neurotrauma. 1999;16(9):783-92.
12. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab. 1999;19(4):443-51.
13. Veech RL, Valeri CR, VanItallie TB. The mitochondrial permeability transition pore provides a key to the diagnosis and treatment of traumatic brain injury. IUBMB Life. 2012;64(2):203-7.
14. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(5 Suppl):S11-4.
15. Chapuis B, Helg C, Jeannet M, et al. Anaphylactic reaction to intravenous cyclosporine. N Engl J Med. 1985;312(19):1259.
16. Kahan BD, Wideman CA, Flechner S, et al. Anaphylactic reaction to intravenous cyclosporin. Lancet. 1984;1(8367):52.
17. Leunissen KML, Waterval PWG, Vanhooff JP. Anaphylactic reaction to intravenous cyclosporin. Lancet. 1985;1(8429):636.
18. Friedman LS, Dienstag JL, Nelson PW, et al. Anaphylactic reaction and cardiopulmonary arrest following intravenous cyclosporine. Am J Med. 1985;78(2):343-5.
19. Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann Allergy Asthma Immunol. 1998;80(2):159-63.
20. van Hooff JP, Bessems P, Beuman GH, et al. Absence of allergic reaction to cyclosporin capsules in patient allergic to standard oral and intravenous solution of cyclosporin. Lancet. 1987;2(8573):1456.
21. Mackie FE, Umetsu D, Salvatierra O, et al. Pulmonary capillary leak syndrome with intravenous cyclosporin A in pediatric renal transplantation. Pediatr Transpl. 2000;4(1):35-8.
22. Howrie DL, Ptachcinski RJ, Griffith BP, et al. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm. 1985;19(6):425-7.
23. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103(4):860-76.
24. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J. 1980;280(6228):1353.
25. Huttel MS, Schou Olesen A, Stoffersen E. Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth. 1980;52(1):77-9.
26. Moneret-Vautrin DA, Laxenaire MC, Viry-Babel F. Anaphylaxis caused by anti-Cremophor EL IgG STS antibodies in a case of reaction to althesin. Br J Anaesth. 1983;55(5):469-71.
27. Briggs LP, Clarke RS, Watkins J. An adverse reaction to the administration of disoprofol (Diprivan). Anaesthesia. 1982;37(11):1099-101.
28. Ramsay MA, Savege TM, Simpson BR, et al. Controlled sedation with alphaxalone-alphadolone. Br Med J. 1974;2(5920):656-9.
29. Thiel G, Hermle M, Brunner FP. Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effect. Clin Nephrol. 1986;25(Suppl 1):S40-2.
30. Verani R. Cyclosporine nephrotoxicity in the Fischer rat. Clin Nephrol. 1986;25(Suppl 1):S9-13.
31. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994;268(2):1051-6.
32. Sanchez H, Bigard X, Veksler V, et al. Immunosuppressive treatment affects cardiac and skeletal muscle mitochondria by the toxic effect of vehicle. J Mol Cell Cardiol. 2000;32(2):323-31.
33. Bowers VD, Locker S, Ames S, et al. The hemodynamic effects of Cremophor-EL. Transplantation. 1991;51(4):847-50.
34. Theis JG, Liau-Chu M, Chan HS, et al. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol. 1995;13(10):2508-16.
35. Liau-Chu M, Theis JG, Koren G. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine. Ann Pharmacother. 1997;31(11):1287-91.
36. Gotardo MA, Monteiro M. Migration of diethylhexyl phthalate from PVC bags into intravenous cyclosporine solutions. J Pharm Biomed Anal. 2005;38(4):709-13.
37. Venkataramanan R, Burckart GJ, Ptachcinski RJ, et al. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am J Hosp Pharm. 1986;43(11):2800-2.
38. Trapani G, Altomare C, Liso G, et al. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem. 2000;7(2):249-71.
39. Mattila MA, Rossi ML, Ruoppi MK, et al. Reduction of venous sequelae of i.v. diazepam with a fat emulsion as solvent. Br J Anaesth. 1981;53(12):1265-8.
40. Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol. 2006;100(2):437-8.
41. Morgan M, Whitwam JG. Althesin. Anaesthesia. 1985;40(2):121-3.
42. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Rockville, MD, USA: United States Department of Health and Human Services, Food and Drug Administration (FDA); 2001.
43. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London, Great Britain: European Medicines Agency (EMA); 2001.
44. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD, USA: United States Department of Health and Human Services, Food and Drug Administration (FDA); 2001.
45. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1992;30(Suppl 1):S51-8.
46. Kanto JH. Propofol, the newest induction agent of anesthesia. Int J Clin Pharmacol Ther Toxicol. 1988;26(1):41-57.
47. Kloover JS, den Bakker MA, Gelderblom H, et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90(2):304-5.
48. Cook AM, Whitlow J, Hatton J, et al. Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use. Expert Opin Drug Saf. 2009;8(4):411-9.
49. Gupta SK, Manfro RC, Tomlanovich SJ, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol. 1990;30(7):643-53.
50. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl. 2010;115:S1-7.
51. Christians U, First MR, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit. 2000;22(3):330-45.
52. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation. 1995;59(4):505-11.
53. Kees F, Bucher M, Schweda F, et al. Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun. Naunyn Schmiedebergs Arch Pharmacol. 2007;375(6):393-9.
54. Christians U, Schmitz V, Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol. 2005;1(4):641-54.
55. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation. 1994;58(6):658-63.
56. Dutta S, Matsumoto Y, Ebling WF. Propofol pharmacokinetics and pharmacodynamics assessed from a Cremophor EL formulation. J Pharm Sci. 1997;86(8):967-9.
57. Fee JP, Dundee JW, Collier PS, et al. Bioavailability of intravenous diazepam. Lancet. 1984;2(8406):813.
58. Fee JP, Collier PS, Dundee JW. Bioavailability of three formulations of intravenous diazepam. Acta Anaesthesiol Scand. 1986;30(4):337-40.
59. Lee M, Min DI, Ku YM, et al. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol. 2001;41(3):317-23.
60. Min DI, Lee M, Ku YM, et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther. 2000;68(5):478-86.